Evidence map›Paper›PMID 34199470›Full record

ReviewCells2021

Astrocyte Networks as Therapeutic Targets in Glaucomatous Neurodegeneration.

Andrew M Boal, Michael L Risner, Melissa L Cooper, Lauren K Wareham, David J Calkins

Open access · goldAbstract readReview
In one paragraph

Review in Cells, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed
1.9field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 37 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Review
  12. Glial connexins in glaucoma.Frontiers in neuroscience · 2025
    Review
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Astrocyte Immune Functions and Glaucoma.International journal of molecular sciences · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Andrew M BoalDepartment of Ophthalmology and Visual Sciences, Vanderbilt Eye Institute, Vanderbilt University Medical Center, 1161 21st Ave S, AA7103D Medical Center North, Nashville, TN 37232-0654, USA.ORCID 0000-0001-9436-8786
Michael L RisnerDepartment of Ophthalmology and Visual Sciences, Vanderbilt Eye Institute, Vanderbilt University Medical Center, 1161 21st Ave S, AA7103D Medical Center North, Nashville, TN 37232-0654, USA.
Melissa L CooperSkirball Institute for Biomolecular Medicine, NYU Langone Medical Center, New York, NY 10016, USA.ORCID 0000-0003-4337-8356
Lauren K WarehamDepartment of Ophthalmology and Visual Sciences, Vanderbilt Eye Institute, Vanderbilt University Medical Center, 1161 21st Ave S, AA7103D Medical Center North, Nashville, TN 37232-0654, USA.
David J CalkinsDepartment of Ophthalmology and Visual Sciences, Vanderbilt Eye Institute, Vanderbilt University Medical Center, 1161 21st Ave S, AA7103D Medical Center North, Nashville, TN 37232-0654, USA.ORCID 0000-0002-8475-9959
Vanderbilt University Medical Center · USNYU Langone Health · US

Funding

MEDICAL SCIENTIST TRAINING PROGRAMT32GM007347 · NIGMS · VANDERBILT UNIVERSITY · PI WILLIAMS, CHRISTOPHER S. · 1985 to 2023
$26.3M
Shop Module CoreP30EY008126 · NEI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI David J. Calkins · 1989 to 2026
$19.6M
Training Systems and Integrative NeuroscienceT32MH019524 · NIMH · NEW YORK UNIVERSITY · PI KIORPES, LYNNE · 1992 to 2025
$5.2M
Medical Scientist Training ProgramT32GM152284 · NIGMS · VANDERBILT UNIVERSITY · PI Christopher S. Williams · 2024 to 2026
$4.8M
Transient Receptor Potential Channels and Retinal Ganglion Cell Death in GlaucomaR01EY017427 · NEI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI CALKINS, DAVID J. · 2008 to 2020
$4.2M
Mechanisms of Synaptic Remodeling and Neuronal Self-Repair in Aging and GlaucomaR01EY024997 · NEI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI David J. Calkins · 2015 to 2026
$3.8M
NEI NIH HHS EY008126NEI NIH HHS EY017427NEI NIH HHS EY024997NIGMS NIH HHS T32 GM007347NIGMS NIH HHS T32 GM152284NIMH NIH HHS T32 MH019524
6 · The paper itself

Abstract

Astrocytes are intimately involved in the response to neurodegenerative stress and have become an attractive target for the development of neuroprotective therapies. However, studies often focus on astrocytes as single-cell units. Astrocytes are densely interconnected by gap junctions that are composed primarily of the protein connexin-43 (Cx43) and can function as a broader network of cells. Such networks contribute to a number of important processes, including metabolite distribution and extracellular ionic buffering, and are likely to play an important role in the progression of neurodegenerative disease. This review will focus on the pro-degenerative and pro-survival influence of astrocyte Cx43 in disease progression, with a focus on the roles of gap junctions and hemichannels in the spread of degenerative stress. Finally, we will highlight the specific evidence for targeting these networks in the treatment of glaucomatous neurodegeneration and other optic neuropathies.

Indexed as

AstrocytesConnexin 43Gap JunctionsGlaucomaHumansNeurodegenerative DiseasesOptic Nerve DiseasesConnexin 43GJA1 protein, humanastrocyteconnexin-43gap junctionglaucoma

Identifiers

PMID34199470
PMCPMC8228804
OpenAlexW3172016039

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.